SAN ANTONIO–(BUSINESS WIRE)–Just in time for back-to-school, Visionworks and Davis Vision is launching ‘Let’s Go See,’ a cause marketing initiative focused on raising awareness about the importance of children receiving an annual eye exam. Reports from The Center for Health in Schools show that about 60% of students classified as problem learners have some sort of undetected visual problem. “Many parents take their children in for routine doctor and dental check-ups, but often wait for their
MIAMI–(BUSINESS WIRE)–For the 12th consecutive year — and the 14th time overall — Bascom Palmer Eye Institute at UHealth – the University of Miami Health System has been ranked the nation’s best in ophthalmology by U.S. News & World Report in its 2015-2016 Best Hospitals edition. Every year since the rankings began 25 years ago, Bascom Palmer has been ranked either first or second in the country. “At Bascom Palmer, the well-being of our patients inspires us to excel in eye care, vision re
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida CEO to speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, this weekend.
SAN JOSE, Calif.–(BUSINESS WIRE)–Saki Corporation announces the relocation of the Saki America office to Fremont, CA. The office will handle sales, training, service and application support for Saki’s 2D and 3D inspection systems.
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Appoints ophthalmology development leader Spivey to Board of Directors
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation announced the appointment of David T. Shima, Ph.D. as Chief Scientific Officer and Henric Bjarke as Senior Vice President and Chief Commercial Officer.
ALPHARETTA, Ga.–(BUSINESS WIRE)–Sally Dillehay, Ed.D, OD, of Visioneering Technologies, Inc. (VTI), has been recognized by Vision Monday as one of the Most Influential Women in Optical for 2015, in the Executive Suite category.
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel approaches for the global eye care market including revolutionary natural non-antibiotic antimicrobial products, today announced that the New York Stock Exchange has accepted NovaBay’s plan to regain compliance with the NYSE MKT’s continued listing standards. As previously disclosed, the NYSE notified the Company on April 28, 2015 that it had fall
STOCKHOLM–(BUSINESS WIRE)–Regulatory News: U.S. Congress has passed a new bill called The Steve Gleason Act that improves the possibility for people with communication disabilities to receive public funding of speech-generating devices (SGDs) through Medicare. President Obama’s subsequent signing of the bill is expected to take place shortly. For Tobii Dynavox, which develops and sells both eye tracking and touchscreen-based assistive technology solutions, the new bill is likely to introduce
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/jtc4tf/myopiapipeline) has announced the addition of the “Myopia-Pipeline Insights” report to their offering. Myopia – Pipeline Insights provides the in-depth ana…
CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced top-line results from its TIME-2 study of AKB-9778 in DME. The combination of AKB-9778 (dosed at 15 mg BID) and Lucentis® (ranibizumab injection) provided a clinically significant benefit in reduction of central subfield thickness (CST) compared to Lucentis® alone (p=0.008). In association with this improvement in CST, a positive trend also sh
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it continues to fortify the patent protection covering its retinal pigment epithelium (RPE) transplant technology for macular degeneration with the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent No 9,080,150. “The issuance of this 9th U.S. patent in our global RPE portfolio represents yet another example of the
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today announced the first commercial implants of the Argus® II Retinal Prosthesis System (“Argus II”) have been performed in Austria and Turkey, and the first implant in Spain through a distribution agreement with IMEX has been performed. IMEX is the largest
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida announces top line results from investigator-sponsored Phase II study of Medidur for uveitis. Statistically significant reduction in recurrence of disease and visual acuity.
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/97mq29/ophthalmology) has announced the addition of the “Ophthalmology Devices Global Market – Forecast To 2021” report to their offering. Ophthalmology is a segm…
ST ALBANS, United Kingdom–(BUSINESS WIRE)–SANTEN launches TAPTIQOM® preservative-free fixed combination eye drops in the UK.
WASHINGTON–(BUSINESS WIRE)–Researchers have harnessed the human eye’s ability to detect subtle color differences and identify ‘thin films’ that differ in thickness by a few nanometers, about the width of a single virus.
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company that has developed and is currently marketing the Presbia Flexivue Microlens™, a revolutionary optical lens implant for treating presbyopia today announced that it has treated over 50% of subjects in the second stage enrollment of its pivotal study. Presbia received FDA approval to commence the second stage of its pivotal study in February, and continues enrollment of subjects at eleven investigational sites acros
NEEDHAM, Mass. & PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, a privately held company focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, announced data from its phase 1 safety study of X-82 at ISOPT.
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, which develops drug therapies to treat eye diseases, to present July 10 at the International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) Clinical meeting in Berlin.